cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14559786
title: A socioeconomic air pollutant emission inventory of 30 Chinese provinces for 2012 and 2017

description: <b>Rapid economic development in recent China were accompanied with severe atmospheric pollution, which has attracted wide concern as its great threaten to human health. Detailed air pollutant inventories by region and socioeconomic sector can help to support the design of pollution control policies from various industrial transformation perspectives. Based on the existing widely used air pollutant inventory——the MEIC model and various energy statistical data, this data description reconstructs the most up-to-data inventory for various particulate matter (including primary PM<sub>2.5</sub>, BC, OC, PM10 and CO) and PM<sub>2.5</sub> precursors (SO<sub>2</sub>, NO<sub>x</sub>, MNVOC and NH<sub>3</sub>) in 46 socioeconomic sectors for 30 Chinese provinces in 2012 and 2017, which can be directly used in various economic models directly. The inventory is an important extension of the MEIC model. As this database covers the most crucial years during the implementation period of the Air Pollution Prevention and Control Action Plan, it offers many opportunities for various scientific research and policy making from an industrial structure perspective.</b>
DOI: 10.6084/m9.figshare.14559786.v1
title: A socioeconomic air pollutant emission inventory of 30 Chinese provinces for 2012 and 2017

description: <b>Rapid economic development in recent China were accompanied with severe atmospheric pollution, which has attracted wide concern as its great threaten to human health. Detailed air pollutant inventories by region and socioeconomic sector can help to support the design of pollution control policies from various industrial transformation perspectives. Based on the existing widely used air pollutant inventory——the MEIC model and various energy statistical data, this data description reconstructs the most up-to-data inventory for various particulate matter (including primary PM<sub>2.5</sub>, BC, OC, PM10 and CO) and PM<sub>2.5</sub> precursors (SO<sub>2</sub>, NO<sub>x</sub>, MNVOC and NH<sub>3</sub>) in 46 socioeconomic sectors for 30 Chinese provinces in 2012 and 2017, which can be directly used in various economic models directly. The inventory is an important extension of the MEIC model. As this database covers the most crucial years during the implementation period of the Air Pollution Prevention and Control Action Plan, it offers many opportunities for various scientific research and policy making from an industrial structure perspective.</b>
DOI: 10.6084/m9.figshare.14559993
title: The association between covid-19 and toxoplasmosis

description: Data set for the paper "<b>Toxoplasmosis: A new risk factor for acquiring SARS-CoV-2 infection and a severe course of Covid-19 disease"</b>
DOI: 10.15468/js4smt
title: First instar nymphs of two peltoperlid stoneflies (Insecta, Plecoptera, Peltoperlidae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Mtow, Shodo, Tsutsumi, Tadaaki (2021): First instar nymphs of two peltoperlid stoneflies (Insecta, Plecoptera, Peltoperlidae). Deutsche Entomologische Zeitschrift 68 (1): 179-188, DOI: http://dx.doi.org/10.3897/dez.68.65540, URL: http://dx.doi.org/10.3897/dez.68.65540
DOI: 10.15468/8ydtu2
title: Brahmaculus gen. nov. (Leotiomycetes, Chlorociboriaceae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Johnston, Peter R., Park, Duckchul, Smith, Matthew E., Mujic, Alija B., May, Tom W. (2021): Brahmaculus gen. nov. (Leotiomycetes, Chlorociboriaceae). MycoKeys 80: 19-43, DOI: http://dx.doi.org/10.3897/mycokeys.80.64435, URL: http://dx.doi.org/10.3897/mycokeys.80.64435
DOI: 10.15468/95728t
title: Multi-gene phylogenetic evidence indicates that Pleurodesmospora belongs in Cordycipitaceae (Hypocreales, Hypocreomycetidae) and Pleurodesmospora lepidopterorum sp. nov. on pupa from China

description: This dataset contains the digitized treatments in Plazi based on the original journal article Chen, Wan-Hao, Han, Yan-Feng, Liang, Jian-Dong, Tian, Wei-Yi, Liang, Zong-Qi (2021): Multi-gene phylogenetic evidence indicates that Pleurodesmospora belongs in Cordycipitaceae (Hypocreales, Hypocreomycetidae) and Pleurodesmospora lepidopterorum sp. nov. on pupa from China. MycoKeys 80: 45-55, DOI: http://dx.doi.org/10.3897/mycokeys.80.66794, URL: http://dx.doi.org/10.3897/mycokeys.80.66794
DOI: 10.6084/m9.figshare.13110172
title: Changes in health-related outcomes among colorectal cancer patients undergoing inpatient rehabilitation therapy: a systematic review of observational and interventional studies

description: Colorectal cancer (CRC) and its treatment can lead to several physical and psychosocial impairments. Cancer rehabilitation aims to reduce morbidity and improve quality of life. The objective of this review was to summarize and evaluate evidence on changes in health-related outcomes among CRC patients undergoing inpatient rehabilitation therapy and on the effectiveness of such treatment. We conducted a systematic literature search including the electronic databases Pubmed and Web of Science to find observational and interventional studies, which investigated changes in health-related outcomes among CRC patients undergoing multidisciplinary inpatient rehabilitation programs or treatment effects. Study findings were synthesized narratively. Eleven studies were eligible and included in this review. Eight patient cohort studies addressed outcomes such as physical and functional status, fecal incontinence, anxiety and depression, and quality of life. Positive changes during rehabilitation therapy were observed for physical health (functional and physical status, fecal incontinence), and several dimensions of quality of life. Study findings concerning anxiety and depression were not conclusive. Studies that additionally conducted long-term follow-ups indicated that the improved health status after rehabilitative treatment waned over time. One RCT reported no effect of inpatient rehabilitation on distress and two randomized trials reported effects of exercise intensity on oxidative stress and immune response. Sample sizes were low (&lt;100 included CRC patients) in eight studies and only the RCT included a comparison group (non-rehabilitants). The scientific evidence level was very limited. Due to the lack of a comparison group in most studies, we were only able to evaluate changes during/after inpatient rehabilitation therapy but not the effectiveness of treatment. However, study findings suggest that physical health and functional independence improve during inpatient rehabilitation, but improvements wane over time. Further large representative studies, in particular RCTs with long-term follow-up, are essential to evaluate the effectiveness of inpatient rehabilitation and identify determinants of treatment success.
DOI: 10.6084/m9.figshare.13110172.v1
title: Changes in health-related outcomes among colorectal cancer patients undergoing inpatient rehabilitation therapy: a systematic review of observational and interventional studies

description: Colorectal cancer (CRC) and its treatment can lead to several physical and psychosocial impairments. Cancer rehabilitation aims to reduce morbidity and improve quality of life. The objective of this review was to summarize and evaluate evidence on changes in health-related outcomes among CRC patients undergoing inpatient rehabilitation therapy and on the effectiveness of such treatment. We conducted a systematic literature search including the electronic databases Pubmed and Web of Science to find observational and interventional studies, which investigated changes in health-related outcomes among CRC patients undergoing multidisciplinary inpatient rehabilitation programs or treatment effects. Study findings were synthesized narratively. Eleven studies were eligible and included in this review. Eight patient cohort studies addressed outcomes such as physical and functional status, fecal incontinence, anxiety and depression, and quality of life. Positive changes during rehabilitation therapy were observed for physical health (functional and physical status, fecal incontinence), and several dimensions of quality of life. Study findings concerning anxiety and depression were not conclusive. Studies that additionally conducted long-term follow-ups indicated that the improved health status after rehabilitative treatment waned over time. One RCT reported no effect of inpatient rehabilitation on distress and two randomized trials reported effects of exercise intensity on oxidative stress and immune response. Sample sizes were low (&lt;100 included CRC patients) in eight studies and only the RCT included a comparison group (non-rehabilitants). The scientific evidence level was very limited. Due to the lack of a comparison group in most studies, we were only able to evaluate changes during/after inpatient rehabilitation therapy but not the effectiveness of treatment. However, study findings suggest that physical health and functional independence improve during inpatient rehabilitation, but improvements wane over time. Further large representative studies, in particular RCTs with long-term follow-up, are essential to evaluate the effectiveness of inpatient rehabilitation and identify determinants of treatment success.
DOI: 10.6084/m9.figshare.12952161
title: Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

description: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma survivors, years after treatment. Therefore, we evaluated HRQoL in long-term advanced melanoma survivors and compared the study outcomes with matched controls without cancer. Ipilimumab-treated advanced melanoma survivors without evidence of disease and without subsequent systemic therapy for a minimum of two years following last administration of ipilimumab were eligible for this study. The European Organization for Research and Treatment of Cancer quality of life questionnaire Core 30 (EORTC QLQ-C30), the Multidimensional Fatigue Inventory (MFI), the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer Therapy-Melanoma questionnaire (FACT-M) were administered. Controls were individually matched for age, gender, and educational status. Outcomes of survivors and controls were compared using generalized estimating equations, and differences were interpreted as clinically relevant according to published guidelines. A total of 89 survivors and 265 controls were analyzed in this study. After a median follow-up of 39 (range, 17–121) months, survivors scored significantly lower on physical (83.7 <i>vs</i>. 89.8, difference (diff) = −5.80, <i>p</i>=.005), role (83.5 <i>vs.</i> 90, diff = −5.97, <i>p</i>=.02), cognitive (83.7 <i>vs.</i> 91.9, diff = −8.05, <i>p</i>=.001), and social functioning (86.5 <i>vs.</i> 95.1, diff = −8.49, <i>p</i>= vs. 15.5, diff = 7.48, <i>p</i>=.004), dyspnea (13.3 <i>vs.</i> 6.7, diff = 6.47 <i>p</i>=.02), diarrhea (7.9 <i>vs.</i> 4.0, diff = 3.78, <i>p</i>=.04), and financial impact (10.5 <i>vs.</i> 2.5, diff = 8.07, <i>p</i>=.001) than matched controls. Group differences were indicated as clinically relevant. Compared to matched controls, long-term advanced melanoma survivors had overall worse functioning scores, more physical symptoms, and financial difficulties. These data may contribute to the development of appropriate survivorship care.
DOI: 10.6084/m9.figshare.12952161.v1
title: Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

description: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma survivors, years after treatment. Therefore, we evaluated HRQoL in long-term advanced melanoma survivors and compared the study outcomes with matched controls without cancer. Ipilimumab-treated advanced melanoma survivors without evidence of disease and without subsequent systemic therapy for a minimum of two years following last administration of ipilimumab were eligible for this study. The European Organization for Research and Treatment of Cancer quality of life questionnaire Core 30 (EORTC QLQ-C30), the Multidimensional Fatigue Inventory (MFI), the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer Therapy-Melanoma questionnaire (FACT-M) were administered. Controls were individually matched for age, gender, and educational status. Outcomes of survivors and controls were compared using generalized estimating equations, and differences were interpreted as clinically relevant according to published guidelines. A total of 89 survivors and 265 controls were analyzed in this study. After a median follow-up of 39 (range, 17–121) months, survivors scored significantly lower on physical (83.7 <i>vs</i>. 89.8, difference (diff) = −5.80, <i>p</i>=.005), role (83.5 <i>vs.</i> 90, diff = −5.97, <i>p</i>=.02), cognitive (83.7 <i>vs.</i> 91.9, diff = −8.05, <i>p</i>=.001), and social functioning (86.5 <i>vs.</i> 95.1, diff = −8.49, <i>p</i>= vs. 15.5, diff = 7.48, <i>p</i>=.004), dyspnea (13.3 <i>vs.</i> 6.7, diff = 6.47 <i>p</i>=.02), diarrhea (7.9 <i>vs.</i> 4.0, diff = 3.78, <i>p</i>=.04), and financial impact (10.5 <i>vs.</i> 2.5, diff = 8.07, <i>p</i>=.001) than matched controls. Group differences were indicated as clinically relevant. Compared to matched controls, long-term advanced melanoma survivors had overall worse functioning scores, more physical symptoms, and financial difficulties. These data may contribute to the development of appropriate survivorship care.
DOI: 10.6084/m9.figshare.13302739
title: Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial

description: Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial
DOI: 10.6084/m9.figshare.13302739.v1
title: Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial

description: Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial
DOI: 10.6084/m9.figshare.12988609.v1
title: Metastatic uveal melanoma managed with best supportive care

description: Metastatic uveal melanoma managed with best supportive care
DOI: 10.6084/m9.figshare.12988609
title: Metastatic uveal melanoma managed with best supportive care

description: Metastatic uveal melanoma managed with best supportive care
DOI: 10.6084/m9.figshare.13067583.v1
title: Oncological therapy to Swedish men with metastatic penile cancer 2000–2015

description: Penile cancer is an uncommon disease with poor prognosis when spread to more than one inguinal lymph node. Recommendations on chemo- and radiotherapy in treatment guidelines are based on low-grade evidence. There are to our knowledge no described population-based cohort with detailed information on given oncological treatment and survival data. The aim of this study is to investigate in detail how men with metastatic penile cancer have been treated with chemotherapy and radiotherapy over time, and how survival varies with N-stage and given treatment. For this observational cohort study all men in Sweden diagnosed with penile cancer with lymph node- or distant metastases 2000-2015 were identified through the Swedish National Penile Cancer Register (NPECR). Medical records were retrieved and 325 men were confirmed to have metastatic penile cancer (T<sub>any</sub>, c or pN1-3 and/or M1). Information on treatments was collected. Causes of death were retrieved from the National Cause of Death Register (CDR). Chemotherapy and/or radiotherapy were given to 172 (53%) of all men. The use of oncological treatments with curative intent increased significantly during the study period, from 30% of men with c/pN2-3 diagnosed 2000–2003 compared with 57% of men diagnosed 2012–2015. Ninety-three (29%) men received oncological treatments with curative intent of whom 85/93 (91%) had stage c/pN2-3M0. Survival decreased with higher N-stage, M1-stage, and absence of oncological treatment with curative intent. For men with c/pN3-stage, the engagement of pelvic lymph nodes was entailed with lower survival than pN3 based on extra-nodal extension (ENE). The use of oncological treatment was below recommendations in guidelines but increased during the study period. Treatment was given predominantly to men with c/pN2-3 and M1-disease. Survival was higher among men treated with curative intent; this could be due to patient selection bias.
DOI: 10.6084/m9.figshare.13067767
title: Quality of life in patients with cancer during the COVID-19 pandemic – a Danish cross-sectional study (COPICADS)

description: The COVID-19 pandemic is an international public health crisis. The risk of getting an infection with COVID-19 might impact the emotional well-being in patients with cancer. The aim of this study was to investigate quality of life (QoL) for patients with cancer during the COVID-19 pandemic. A cross-sectional survey, including questions about demographics, concerns of COVID-19 impact on cancer treatment and outpatient clinic visits, and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire was sent to patients with cancer at the Department of Oncology, Odense University Hospital, Denmark. The survey was open from 15<sup>th</sup> May to 29<sup>th</sup> May 2020, and 4.571 responded. Results were compared to the Danish ‘Barometer Study’ conducted by the Danish Cancer Society to elucidate experiences with the Danish healthcare system prior to COVID-19 pandemic. In total, 9% of patients with cancer had refrained from consulting a doctor or the hospital due to fear of COVID-19 infection, and 80% were concerned about contracting COVID-19 to some extent. Seventeen patients were tested positive for COVID-19. The mean global QoL and emotional functioning (EF) scores were 71.3 and 82.8, respectively. In comparison to the ‘Barometer Study’, no clinical significant differences in QoL and EF scores were observed. Multivariate analysis demonstrated that being ‘Concerned about contracting corona-virus’ was correlated with lower QoL and EF scores. Factors associated with being concerned of contracting COVID-19 were comorbid conditions, incurable cancer, receiving medical cancer treatment and female gender. Danish patients with cancer during the COVID-19 pandemic did not have lower scores of QoL and emotional functioning compared to the Danish ‘Barometer Study’. However, the study suggests that concerns of contracting COVID-19 was correlated with lower scores of QoL.
DOI: 10.6084/m9.figshare.13067767.v1
title: Quality of life in patients with cancer during the COVID-19 pandemic – a Danish cross-sectional study (COPICADS)

description: The COVID-19 pandemic is an international public health crisis. The risk of getting an infection with COVID-19 might impact the emotional well-being in patients with cancer. The aim of this study was to investigate quality of life (QoL) for patients with cancer during the COVID-19 pandemic. A cross-sectional survey, including questions about demographics, concerns of COVID-19 impact on cancer treatment and outpatient clinic visits, and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire was sent to patients with cancer at the Department of Oncology, Odense University Hospital, Denmark. The survey was open from 15<sup>th</sup> May to 29<sup>th</sup> May 2020, and 4.571 responded. Results were compared to the Danish ‘Barometer Study’ conducted by the Danish Cancer Society to elucidate experiences with the Danish healthcare system prior to COVID-19 pandemic. In total, 9% of patients with cancer had refrained from consulting a doctor or the hospital due to fear of COVID-19 infection, and 80% were concerned about contracting COVID-19 to some extent. Seventeen patients were tested positive for COVID-19. The mean global QoL and emotional functioning (EF) scores were 71.3 and 82.8, respectively. In comparison to the ‘Barometer Study’, no clinical significant differences in QoL and EF scores were observed. Multivariate analysis demonstrated that being ‘Concerned about contracting corona-virus’ was correlated with lower QoL and EF scores. Factors associated with being concerned of contracting COVID-19 were comorbid conditions, incurable cancer, receiving medical cancer treatment and female gender. Danish patients with cancer during the COVID-19 pandemic did not have lower scores of QoL and emotional functioning compared to the Danish ‘Barometer Study’. However, the study suggests that concerns of contracting COVID-19 was correlated with lower scores of QoL.
DOI: 10.6084/m9.figshare.13176105
title: Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data

description: Cancer patients suffer from worse coronavirus disease-2019 (COVID-19) outcomes. Whether active oncologic treatment is an additional risk factor in this population remains unclear. Therefore, here we have conducted a systematic review and meta-analysis to summarize the existing evidence for the effect of active oncologic treatment on COVID-19 outcomes. Systematic search of databases (PubMed, Embase) was conducted for studies published from inception to July 1, 2020, with a subsequent search update conducted on 10 October 2020. In addition, abstracts and presentations from major conference proceedings (ASCO, ESMO, AACR) as well as pre-print databases (medxriv, bioxriv) were searched. Retrospective and prospective studies reporting clinical outcomes in cancer patients with laboratory confirmation or clinical diagnosis of COVID-19 and details of active or recent oncologic treatment were selected. Random-effects model was applied throughout meta-analyses. Summary outcome measure was the pooled odds ratio (OR) of death for active cancer therapy versus no active cancer therapy for each of the following modalities: recent surgery, chemotherapy, targeted therapy, immunotherapy, or chemoimmunotherapy. Sixteen retrospective and prospective studies (3558 patients) were included in the meta-analysis. Active chemotherapy was associated with higher risk of death compared to no active chemotherapy (OR, 1.60, 95% CI, 1.14–2.23). No significant association with risk of death was identified for active targeted therapy, immunotherapy, chemoimmunotherapy, or recent surgery. Meta-analysis of multivariate adjusted OR of death for active chemotherapy was consistently associated with higher risk of death compared to no active chemotherapy (OR, 1.42, 95% CI, 1.01–2.01). Active chemotherapy appears to be associated with higher risk of death in cancer patients with COVID-19. Further research is necessary to characterize the complex interactions between active cancer treatment and COVID-19.